Michael J. Droller

Michael J. Droller's AcademicInfluence.com Rankings

Michael J. Droller

Engineering

#7468

World Rank

#8844

Historical Rank

Biomedical Engineering

#759

World Rank

#771

Historical Rank

engineering Degrees

Michael J. Droller

Philosophy

#9929

World Rank

#13559

Historical Rank

Logic

#6881

World Rank

#8439

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Michael J. Droller's Degrees

Doctorate Medicine Stanford University

Why Is Michael J. Droller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael J. Droller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. (2005) (421)
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. (2013) (372)
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. (2007) (300)
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. (2007) (277)
Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial (1999) (271)
The effect of age and gender on bladder cancer: a critical review of the literature (2010) (268)
A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells. (1978) (233)
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. (2013) (221)
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (2000) (199)
The natural history of bladder cancer. Implications for therapy. (2000) (192)
Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. (2002) (185)
Prevention of cyclophosphamide-induced hemorrhagic cystitis. (1982) (175)
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. (2005) (172)
Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity (1998) (161)
Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus (2014) (156)
AN ELECTRON MICROSCOPE STUDY OF YOLK FORMATION DURING OOGENESIS IN LEBISTES RETICULATUS GUPPYI (1966) (133)
Bladder cancer in the elderly. (2009) (128)
New optical imaging technologies for bladder cancer: considerations and perspectives. (2012) (120)
Bladder cancer: State‐of‐the‐art care (1998) (120)
Advanced patient age is associated with inferior cancer‐specific survival after radical nephroureterectomy (2009) (116)
Enhancement of natural and antibody-dependent lymphocyte cytotoxicity by drugs which inhibit prostaglandin production by tumor target cells. (1978) (106)
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer (2018) (88)
C‐reactive protein is significantly associated with prostate‐specific antigen and metastatic disease in prostate cancer (2005) (84)
Clinical and laboratory studies into the pathogenesis of malacoplakia. (1976) (76)
Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? (2012) (75)
Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. (1993) (75)
Urologic Oncology: Seminars and Original Investigations - Introduction (2003) (71)
Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s) (2010) (69)
Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. (2001) (63)
In vitro enhancement of natural and antibody-dependent lymphocyte-mediated cytotoxicity against tumor target cells by interferon. (1979) (54)
Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. (2006) (52)
A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. (2002) (51)
An approach to the control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. (1978) (50)
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. (2014) (49)
Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. (2002) (47)
Micropapillary bladder cancer: current treatment patterns and review of the literature. (2014) (46)
Improved detection of recurrent bladder cancer using the bard BTA stat test. (1998) (46)
Production of prostaglandin E2 by bladder tumor cells in tissue culture and a possible mechanism of lymphocyte inhibition. (1979) (45)
Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. (2000) (44)
Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. (2002) (40)
Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. (2000) (38)
FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma (2004) (38)
Molecular pathology of non-invasive urothelial carcinomas (part I) (2003) (36)
A role for the macrophage in in vivo and in vitro resistance to murine bladder tumor cell growth. (1975) (33)
The controversial role of radiation therapy as adjunctive treatment of bladder cancer. (1983) (33)
Current concepts in assessment and treatment of bladder cancer (2000) (32)
Surveillance and management of recurrence for upper tract transitional cell carcinoma. (2003) (32)
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? (2013) (31)
Production of prostaglandin E2 by tumor cells in vitro. (1980) (28)
Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. (2002) (27)
THE ETIOLOGY OF BLADDER CANCER‐ARE THERE ANY NEW CLUES OR PREDICTORS OF BEHAVIOR? (1995) (26)
Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. (1987) (26)
Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. (2002) (25)
Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. (2002) (25)
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide. (2000) (24)
Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. (2002) (24)
Thrombin-induced increase in intracellular cyclic 3',5'-adenosine monophosphate in human platelets. (1972) (24)
Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. (1982) (23)
Bladder Cancer: Chemoprevention, complementary approaches and budgetary considerations (2008) (22)
EDITORIAL: MARKERS IN BLADDER CANCER-ISSUES TO CONSIDER (1998) (22)
Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe? (1985) (22)
Bacillus Calmette-Guerin in the management of bladder cancer. (1986) (21)
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. (2002) (20)
Medical approaches in the management of prostatic disease. (1997) (19)
Assessing the quality of studies on the diagnostic accuracy of tumor markers. (2014) (19)
Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. (2003) (19)
Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. (1998) (19)
Ultrastructure of the platelet release reaction in response to various aggregating agents and their inhibitors. (1973) (18)
Current concepts of tumor markers in bladder cancer. (2002) (18)
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. (1997) (18)
Ureteral Replacement Using Porcine Small Intestine Submucosa in a Porcine Model (2004) (17)
Biological considerations in the assessment of urothelial cancer: a retrospective. (2005) (17)
Ultrastructural visualization of the thrombin-induced platelet release reaction. (2009) (17)
Urinary telomerase and its possible role as a marker for bladder cancer. (1998) (17)
Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. (2016) (16)
Urothelial cancer--mucosally confined disease can be aggressive. (2000) (15)
Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. (2002) (15)
Serum Androgen Levels in Healthy Premenopausal Women With and Without Sexual Dysfunction: Part A. Serum Androgen Levels in Women Aged 20–49 Years With No Complaints of Sexual Dysfunction (2004) (14)
Muscle-invasive bladder cancer: does it arise de novo or from pre-existing superficial disease? (1989) (14)
Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. (2016) (14)
Lymphocyte and macrophage adenyl cyclase activity in animals with enhanced cell-mediated resistance to infection and tumors. (1975) (14)
Markers in bladder cancer--issues to consider. (1998) (13)
Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). (2003) (13)
Enhancement of natural cytotoxicity in lymphocytes from animals with carcinogen-induced bladder cancer. (1983) (12)
Surgical Management of Urologic Disease: An Anatomic Approach (1992) (12)
Interferon induction and prostaglandin synthetase inhibition in the in vitro and in vivo manipulation of immune response expression in an animal model of bladder cancer. (1982) (11)
Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? (1983) (11)
Prostaglandins and neoplasia. (1981) (11)
Risk of continued intravesical therapy and delayed cystectomy in the BCG-refractory superficial bladder cancer: an investigational approach. (2002) (11)
Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: requirements for direct contact and lymphocyte viability. (1980) (11)
Anatomic considerations in extraperitoneal approach to radical nephrectomy. (1990) (10)
BLADDER, PENIS AND URETHRAL CANCER, AND BASIC PRINCIPLES OF ONCOLOGY (2001) (10)
Indomethacin and poly I:C in the inhibition of carcinogen-induced bladder cancer in an experimental animal model. (1984) (10)
It's a matter of time. (2011) (10)
264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
Treatment of regionally advanced bladder cancer. An overview. (1992) (10)
Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. (2002) (10)
263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder (2004) (9)
Expression of the cellular immune response during tumor development in an animal model of bladder cancer. (1982) (9)
Treatment modalities in superficial bladder cancer. (1989) (9)
Biologic response modifiers in genitourinary neoplasia (1987) (9)
Obstruction of ischemic ureteropelvic junction. (1974) (9)
New Gleason grading system: Statement from the Editors of six journals. (2016) (9)
Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. (2003) (9)
Thiotepa effects on urinary cytology in the interpretation of transitional cell cancer. (1985) (8)
Intracavitary bacillus Calmette-Guérin for Superficial Bladder Tumors. (2017) (8)
Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder. (2003) (8)
Cancer patient advocacy: new opportunities for treatment advances. (2007) (8)
A Systematic Overview of Radiation Therapy Effects in Urinary Bladder Cancer (2004) (8)
Localization cytology in urothelial carcinoma. (1977) (7)
WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. (1999) (7)
Perspectives on prostate cancer diagnosis and treatment: a roundtable. (2001) (7)
BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer. (2010) (7)
Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. (2002) (7)
Consensus guidelines for reporting prostate cancer Gleason Grade (2016) (7)
Screening for bladder cancer: Theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease (2008) (7)
Update on oncogenes and relevance in urology. (1987) (6)
Premalignant Lesions and Carcinoma in situ in Bladder Neoplasia: Introduction and Overview (2000) (6)
DD23 Biomarker. A Prospective Clinical Assessment in Routine Urinary Cytology Specimens From Patients Being Monitored for TCC (2004) (6)
An electron microscope study of the time course of platelet nucleotide, calcium, and acid phosphatase secretion. (1974) (6)
Uncertain role of cAMP in platelet function. (1972) (6)
T1G3 Transitional Cell Carcinoma of the Bladder: Recurrence, Progression and Survival (2004) (6)
Applications of telomerase in urologic oncology (2005) (6)
Comprehensive handbook for developing a bladder cancer cystectomy database. (2013) (5)
Environment and The Genitourinary Tract (1996) (5)
Interferon: a perspective. (1980) (5)
Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach (2020) (5)
Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. (2003) (4)
Editorial: urothelial tumors--liberal applications of conservative approaches. (2003) (4)
Thrombin-induced platelet prostaglandin and cyclic AMP production and a possible intrinsic modulation of platelet function. (2009) (4)
577 Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis (2013) (4)
Modulation of stimulatory effects of poly(I:C) on natural cytotoxicity by anti-interferon. (1984) (4)
Editorial: Bladder Cancer (1994) (4)
Primary care update on kidney and bladder cancer: a urologic perspective. (2004) (4)
Prostaglandins and Expression of Lymphocyte Cytotoxicity (1985) (4)
Immunohistochemical Analysis of NAD(P)H:Quinone Oxidoreductase and NADPH Cytochrome P450 Reductase in Human Superficial Bladder Tumours: Relationship Between Tumour Enzymology and Clinical Outcome Following Intravesical Mitomycin C Therapy (2004) (4)
Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. (1998) (4)
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. (2001) (4)
Bladder cancer: From pathogenesis to prevention (2008) (3)
Bladder cancer. (1981) (3)
Changing aspects in residency education. (2005) (3)
Editorial: New Efforts to Stage Bladder Cancer (1995) (3)
Nafarelin acetate and benign prostatic hyperplasia. (1988) (3)
The natural history of invasive bladder cancer and the case against definitive radiation therapy (1985) (3)
Controversies in urologic oncology. (1988) (3)
Consensus guidelines for reporting prostate cancer Gleason Grade (2016) (3)
A rose is a rose is a rose, or is it? (1986) (3)
Stage Grouping. (2016) (3)
Risk factors in clonal development from superficial to invasive bladder cancer. (1998) (3)
Evolution of a Journal (2015) (2)
Editorial Statement on Gleason Scoring for Prostate Cancer. (2016) (2)
Macrophage depletion and manipulation of enhanced immune response in an animal model of bladder cancer. (1984) (2)
Predictive Markers and Cancer Prevention. Urinary IL-2 Assay for Monitoring Intravesical Bacillus Calmette-Guérin Response of Superficial Bladder Cancer During Induction Course and Maintenance Therapy (2004) (2)
Bacterial infection of renal calculus. (1977) (2)
Bladder cancer: pebbles to reach the water. (1979) (2)
Vigilance, vigilance, vigilance. (2010) (2)
Re: Consensus Guidelines for Reporting Prostate Cancer (2016) (2)
Evaluation and Management of Low-Grade, Low-Stage Bladder Cancer (2001) (2)
Bladder cancer. (2020) (2)
Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. (2001) (2)
New efforts to stage bladder cancer. (1995) (2)
A new vision for clinical research. (2012) (2)
Production of Prostaglandin E 2 by Tumor Cells in Vitro 1 (2006) (2)
Immunotherapy and genitourinary neoplasia: An overview (1986) (1)
Association of cyclooxygenase-2 expression with prognosis of state T1 grade 3 bladder cancer. (2003) (1)
A guideline for discussion and some thoughts. (2009) (1)
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies (2000) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
Citizenship in our profession. (2010) (1)
Differences in adenylate cyclase activities in murine normal cells and bladder tumor cells in tissue culture. (1976) (1)
Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. (1998) (1)
Markers for recurrence of superficial bladder cancer: what is valid? (2000) (1)
A Model for 3-Dimensional Growth of Bladder Cancers to Investigate Cell-Matrix Interactions (2004) (1)
Public education: the AUA and AUA foundation. (2005) (1)
Distal ureteral regeneration after radical transurethral bladder tumor resection (2000) (1)
Maintenance therapy for superficial bladder cancer. (2001) (1)
Oncocytoma and metastatic potential: myth or reality? (1987) (1)
A Commentary on Suramin Demonstrates in Vitro Toxicity against Transitional Cell Carcinoma Cell Lines and Exposure to Alkyllysophospholipids Inhibits in Vitro Invasion of Transitional Cell Carcinoma (1994) (1)
Intravesical chemotherapy in the management of carcinoma in situ of the urinary bladder (1983) (1)
PRINCIPLES OF ONCOLOGY AND IMMUNOLOGY, AND TUMORS OF BLADDER, PENIS AND URETHRA (2000) (1)
Urologic Oncology: Seminars and Original Investigations. A Twenty-Fifth Anniversary History. (2021) (1)
Superficial bladder disease: case studies and therapeutic advances. (1992) (1)
Promoting surgeon-scientists in urologic oncology: The role of our journal. (2009) (1)
Note by Editor (2007) (1)
Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. (2003) (1)
25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. (2022) (1)
Standardization in pathologic assessment of transitional cell cancer of the bladder. (1998) (1)
Editorial Comment: Extending the Domain of Minimally Invasive Surgery: Bladder Cancer (2001) (1)
Effect of intravesical instillations on the human complement factor H related protein (BTA stat) Test. (2002) (1)
The Management of Bladder Cancer (1988) (1)
Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. (2002) (0)
Definitive radiation therapy and bladder cancer: do results reflect intrinsic tumor character? (1984) (0)
Oncogenes and genitourinary neoplasia (1987) (0)
Recent residency training programs in the USA : looking forward to the 21st century : シンポジウムII : 第50回東部総会 (1986) (0)
Photosensitization treatment in bladder cancer. (1988) (0)
[Bladder cancer: understanding the disease and future implications for assessment and therapy]. (2006) (0)
Bladder Cancer: Principles of Combination Therapy. Edited by R.T.D.Oliver, W.F.Hendry and H.J.G.Bloom. Woburn, Massachusetts: Butterworths Publishers, Inc.1981. (1982) (0)
Clinical and laboratory studies into the pathogenesis of malacoplakia Report of Cases CASE (0)
Urologic cancer--when is less more? (2007) (0)
This Month in Investigative Urology: Photosensitization Treatment in Bladder Cancer (1988) (0)
Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma (2004) (0)
Introduction to the 25th anniversary issue (2021) (0)
Immunotherapy in genitourinary neoplasia. (1985) (0)
Immuno peroxidase detection of carcino embryonic antigens and blood group substances in transitional cell carcinomas of the bladder (1981) (0)
Chairmen's Summary (2008) (0)
Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. (2003) (0)
Bladder cancer: the power of study design, interpretation of data and clinical application. (1995) (0)
Comparison of Telomerase Activity and Matrix Metalloproteinase-9 in Voided Urine and Bladder Wash Samples as a Useful Diagnostic Tool for Bladder Cancer (2004) (0)
Seminar article Bladder cancer in the elderly (2009) (0)
This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma. (1994) (0)
The scope of urological interaction: Endless open sky (2011) (0)
Ummunotherapy of metastatic renal cell carcinoma with polyonosinic-polycytidylic acid (1987) (0)
Management and Prognosis of Transitional Cell Carcinoma Superficial Recurrence in Muscle-Invasive Bladder Cancer After Bladder Preservation (2004) (0)
Legends in Urology. (2016) (0)
Considerations in Immunotherapy of Genitourinary Neoplasia (1991) (0)
Controversies in T1 bladder Ca: Early cystectomy vs. TUR (2003) (0)
When is a cancer a malignancy? (2004) (0)
Editorial Comment: Treatment of Advanced Bladder Cancer With Combined Preoperative Irradiation and Radical Cystectomy Versus Radical Cystectomy Alone (1997) (0)
Editorial Comment: Diagnostic Accuracy of Urinary Cytology, and Deoxyribonucleic Acid Flow Cytometry and Cytology on Bladder Washings During Followup for Bladder Tumors (1997) (0)
Prognostic value of p53 overexpression in T1G3 bladder tumours treated with bacillus Calmette-Guérin therapy. (2002) (0)
Seminar article BCAN Think Tank session 1: Overview of risks for and causes of bladder cancer 1 (2010) (0)
To Accept or Not to Accept: Perspectives on Publication (2011) (0)
WITHDRAWN: Introducing the Asian Journal of Urology (2014) (0)
Editorial Comment: Transurethral Ultrasonographic Assessment of Bladder Carcinoma (1995) (0)
Society of Urologic OncologyIntroduction (1999) (0)
Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016; 195: 1723 (2016) (0)
Atlas of Bladder Carcinoma (1986) (0)
New steps forward for Urologic Oncology. (2013) (0)
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. (2000) (0)
Commentary (Droller): Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer (2002) (0)
In Reply to Samaratunga et al. (2016) (0)
A history of the Society of Urologic Oncology. (2021) (0)
Chapter 17 – Diagnosis and Staging of Bladder Cancer (2005) (0)
A Tribute to Allen: Patient Needs and Options in Health Care. (2022) (0)
Photodynamic Therapy for Refractory Superficial Bladder Cancer: Long-Term Clinical Outcomes of Single Treatment Using Intravesical Diffusion Medium (2004) (0)
Invasive transitional cell cancer in the elderly (2007) (0)
UROLOGICAL SURVEY: ABSTRACTSUrological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology (2003) (0)
Therapy and Prophylaxis of Superficial Bladder CarcinomasHulandH. and KlosterhalfenH.: New York: Thieme-Stratton, Inc.1985: 112. 53 figures, 47 tables. (1986) (0)
1293 A META-ANALYSIS OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
Bladder Cancer. Edited by P.H.Smith and G.R.Prout. London: Butterworth, Inc.1984: 275. 78 figures, 53 tables. (1985) (0)
Peer review of guidelines, best practice statements and new documents: what this means for how we use them. (2008) (0)
Phase I Study of Gemcitabine and Radiotherapy Plus Cisplatin After Transurethral Resection as Conservative Treatment for Infiltrating Bladder Cancer (2004) (0)
Introducing the Asian Journal of Urology (2014) (0)
Reproductive infertility microsurgery in the male and female. Sherman J. Silber, 418pp, Williams and Wilkins, Baltimore, MD, 1984, $58.95 (1985) (0)
, H. Huland, H. Klosterhalfen. Thieme-Stratton, Inc., New York (1985), 112, 53 figures, 47 tables (1986) (0)
Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. (2016) (0)
Editorial Comment: Lymphatogenous Spread of Renal Cell Carcinoma (1997) (0)
Preface urologic issues for the internist. (2011) (0)
Letter from the Editor, “Thank you”, Michael J. Droller, M.D. (2020) (0)
George Russell Prout Jr., M.D., 1924-2013, founding editor, urologic oncology. (2014) (0)
UROLOGY FOUNDED IN 1917 BY HUGH HAMPTON YOUN G (1990) (0)
Evaluation of the clinical value of urinary NMP22 as a marker for screening and surveillance of transitional cell carcinoma of the urinary bladder. (2002) (0)
Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. (2002) (0)
Bladder cancer. (1997) (0)
Bladder cancer. (1994) (0)
Inhibition of Tumor Growth in Association with Modification of in Vivo Immune Response by Indomethacin and Polyinosinic:Polycytidylic Acid1 (2006) (0)
Comprar Urologic issues for the Internist, An Issue of Medical Clinics of North America | Michael J. Droller | 9781437724660 | Saunders (2010) (0)
We need to lead and not be led. (2006) (0)
An editor's considerations in publishing industry-sponsored studies. (2015) (0)
Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. (2006) (0)
, R.T.D. Oliver, W.F. Hendry, H.J.G. Bloom (Eds.). Butterworths Publishers, Inc., Woburn, Massachusetts (1981) (1982) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael J. Droller?

Michael J. Droller is affiliated with the following schools:

Michael J. Droller's Academic­Influence.com Rankings

Michael J. Droller's Degrees

Why Is Michael J. Droller Influential?

Michael J. Droller's Published Works

Published Works

What Schools Are Affiliated With Michael J. Droller?

Michael J. Droller's AcademicInfluence.com Rankings